Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Vitamin D as a promising anticancer agent.

Chakraborti CK.

Indian J Pharmacol. 2011 Apr;43(2):113-20. doi: 10.4103/0253-7613.77335.

2.

Vitamin D and systemic cancer: is this relevant to malignant melanoma?

Osborne JE, Hutchinson PE.

Br J Dermatol. 2002 Aug;147(2):197-213. Review.

PMID:
12174089
3.

Seasonal and geographical variations in lung cancer prognosis in Norway. Does Vitamin D from the sun play a role?

Porojnicu AC, Robsahm TE, Dahlback A, Berg JP, Christiani D, Bruland OS, Moan J.

Lung Cancer. 2007 Mar;55(3):263-70. Epub 2007 Jan 17.

PMID:
17207891
4.

19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia.

Kumagai T, Shih LY, Hughes SV, Desmond JC, O'Kelly J, Hewison M, Koeffler HP.

Cancer Res. 2005 Mar 15;65(6):2488-97.

5.

The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer.

Krishnan AV, Swami S, Feldman D.

Steroids. 2012 Sep;77(11):1107-12. doi: 10.1016/j.steroids.2012.06.005. Epub 2012 Jul 16. Review.

6.

Mechanistic Insights of Vitamin D Anticancer Effects.

Ma Y, Johnson CS, Trump DL.

Vitam Horm. 2016;100:395-431. doi: 10.1016/bs.vh.2015.11.003. Epub 2016 Jan 13. Review.

PMID:
26827961
7.

Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy.

Trump DL, Deeb KK, Johnson CS.

Cancer J. 2010 Jan-Feb;16(1):1-9. doi: 10.1097/PPO.0b013e3181c51ee6. Review.

8.

Vitamin D compounds: clinical development as cancer therapy and prevention agents.

Trump DL, Muindi J, Fakih M, Yu WD, Johnson CS.

Anticancer Res. 2006 Jul-Aug;26(4A):2551-6.

9.

Combination of calcitriol and dietary soy exhibits enhanced anticancer activity and increased hypercalcemic toxicity in a mouse xenograft model of prostate cancer.

Wang JY, Swami S, Krishnan AV, Feldman D.

Prostate. 2012 Nov;72(15):1628-37. doi: 10.1002/pros.22516. Epub 2012 Mar 27.

10.

In vitro and in vivo anticancer effects of the novel vitamin E ether analogue RRR-alpha-tocopheryloxybutyl sulfonic acid in prostate cancer.

Ni J, Mai T, Pang ST, Haque I, Huang K, DiMaggio MA, Xie S, James NS, Kasi D, Chemler SR, Yeh S.

Clin Cancer Res. 2009 Feb 1;15(3):898-906. doi: 10.1158/1078-0432.CCR-08-1087.

11.

The p38 and JNK pathways cooperate to trans-activate vitamin D receptor via c-Jun/AP-1 and sensitize human breast cancer cells to vitamin D(3)-induced growth inhibition.

Qi X, Pramanik R, Wang J, Schultz RM, Maitra RK, Han J, DeLuca HF, Chen G.

J Biol Chem. 2002 Jul 19;277(29):25884-92. Epub 2002 Apr 30.

12.

Vitamin D and cancer.

Ali MM, Vaidya V.

J Cancer Res Ther. 2007 Oct-Dec;3(4):225-30. Review.

13.

Can dicoumarol be used as a gonad-safe anticancer agent: an in vitro and in vivo experimental study.

Aras D, Cinar O, Cakar Z, Ozkavukcu S, Can A.

Mol Hum Reprod. 2016 Jan;22(1):57-67. doi: 10.1093/molehr/gav065. Epub 2015 Nov 26.

PMID:
26612783
14.

The anti-cancer actions of vitamin D.

Chiang KC, Chen TC.

Anticancer Agents Med Chem. 2013 Jan;13(1):126-39. Review.

PMID:
23094926
15.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
16.

SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.

Cao ZX, Zheng RL, Lin HJ, Luo SD, Zhou Y, Xu YZ, Zeng XX, Wang Z, Zhou LN, Mao YQ, Yang L, Wei YQ, Yu LT, Yang SY, Zhao YL.

Cell Physiol Biochem. 2011;27(5):565-74. doi: 10.1159/000329978. Epub 2011 Jun 15.

17.

Vitamin D and prostate cancer.

Tuohimaa P, Lyakhovich A, Aksenov N, Pennanen P, Syvälä H, Lou YR, Ahonen M, Hasan T, Pasanen P, Bläuer M, Manninen T, Miettinen S, Vilja P, Ylikomi T.

J Steroid Biochem Mol Biol. 2001 Jan-Mar;76(1-5):125-34.

PMID:
11384870

Supplemental Content

Support Center